PharmEasy Reports ₹5,872 Cr Revenue in FY25, Burn Flat

PharmEasy, one of India’s largest e-pharmacies, reported revenue of ₹5,872 crore for FY25, showing stable performance with controlled expenses. Despite the tough funding environment, the company managed to keep its cash burn flat compared to the previous year, signaling operational discipline. PharmEasy focused on cost optimization, expansion of its diagnostics vertical, and improving margins across core pharmacy sales. The performance highlights the firm’s resilience after regulatory challenges and funding pressures faced in the past two years. Analysts believe that while growth has slowed, steady revenue with controlled burn enhances prospects for sustainable operations and potential IPO plans in the future. The report reflects ongoing consolidation in India’s health-tech sector.